Docket No.

264837US0X PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kenichi KOYAKUMARU, et al.

SERIAL NO: 10/521,800 GAU: 1625

FILED: August 2, 2005 EXAMINER:
FOR: PROCESS FOR PRODUCING 5-(2'-PYRIDYL)-2-PYRIDONE DERIVATIVE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the reference(s) cited in the attached Supplementary European Search Report and listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03) Jay E. Rowe, Jr. Registration No. 58, 948

					5				
Form PTO 1449 (Modified)		U.S. DEPARTMENT OF PATENT AND TRADE	F COMMERCE MARK OFFICE	ATTY DOCKET NO. JUN 8 264837USOX PC TRAPE	E)	SERIAL N			
			264837US0X PCT 10/521,800						
LIST OF	DEEE	RENCES CITED BY APP	LICANT						
LISTOF	KEFE	REINCES CITED BY AFF	LICANI	Kenichi KOYAKUMARU, et al.					
				FILING DATE		GROUP			
				August 2, 2005	1625				
U.S. PATENT DOCUMENTS									
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS			
	AA								
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	AH			***					
	Al				-				
	AJ								
	AK								
1	AL								
	AM				<u> </u>				
				LANGE TO SECOND	 				
	AN	<u> </u>		<u> </u>					
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	UNTRY		TRANSLATION YES NO		
	AO								
	AP								
	AQ					_			
	AR								
	AS		•						
	AT			-					
	AU								
	AV								
		OTUED DEF	EDENOES (Including Author Title Date Bertinen	4 Dansa a	١٠.٠			
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)									
	AW	John R. PROUDFOOT, et al. "NOVEL NON-NUCLEOSIDE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) REVERSE TRANSCRIPTASE. 4. 12-SUBSTITUTED DIPYRIDODIAZEPINONES AS POTENT INHIBITORS OF BOTH WILD-TYPE AND CYSTEINE-181 HIV-1 REVERSE TRANSCRIPTASE ENZYMES", JOURNAL OF MEDICINAL CHEMISTRY, XP-002031262, Vol. 38, No. 24, 1995, Pages 4830-4838							
	AX								
	AY								
	AZ				Additional References sheet(s) attached				
Examiner					Date Considered				
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									